Creo Medical Group plc, a medical device company focused on the emerging field of surgical endoscopy, announces a trading update for the first quarter of 2022 and confirms that it expects to publish its final results for the year ended 31 December 2021 in early May 2022.

Creo continued to build momentum during 2021 and, as announced in the Company’s 3 February 2022 trading update, overall revenue for the year ended 31 December 2021 is expected to be just over £25m – in line with the upgraded market expectations for FY2021. This momentum has continued in 2022 YTD with Creo seeing a solid start to the year. Revenues for Q1 2022 are strong, supported by the commercial groundwork put in place during the COVID-19 pandemic, the reopening of markets post COVID-19 and the resultant backlog of demand for elective procedures, increased training and adoption of Creo’s Speedboat Inject device.

Commercial activity from Creo’s core products continues to grow, with notable contributions from the US, EMEA and Asia-Pacific (“APAC”) markets where case volumes have increased quarter-on-quarter.

Positively, March 2022 was the highest month on record for cases performed in the US, as more physicians adopt Speedboat Submucosal Dissection (“SSD”) for resections in the colon and functional disorders in the oesophagus and stomach. Best in class training and mentoring programmes are helping leading academic and community hospitals deliver minimally invasive advanced endoscopic surgical procedures.
The acquisition of Albyn Medical, bringing direct sales representation and complementary products to the Group, has led to significant growth of users and training sites in UK, Spain, France, and Belgium. Leading physician mentors recently launched a new ‘pioneer’ training programme for large groups of interventional endoscopists and surgeons. These forums will be the standard for onboarding new physicians and institutions.

Creo has now officially opened its regional hub in Singapore, with the facility providing a multi-functional centre for the commercial roll-out of Creo’s products across the APAC region, providing a direct sales and marketing presence across APAC and will be central to the management of Creo’s distribution partners in the APAC region.

Whilst many of the APAC countries are emerging from the COVID-19 pandemic slower than western economies, the Creo APAC team have utilised their extensive experience to build strong relationships with distribution partners in the region and to commence the initial steps required to commercialise products as and when their respective markets allow.

Since the start of the COVID-19 pandemic, Creo has increased the number of distribution partners engaged in the APAC region, all of which will be directly managed through the regional hub. Partners are selected to ensure that they have the necessary experience to not only sell Creo’s core technology in their respective markets but to also work alongside Creo’s clinical education team to ensure that Creo’s training led strategy is replicated.